The development of an NfL assay in plasma follows a greater trend in the AD community focused on developing plasma biomarkers to measure β‐amyloid (Aβ)6, 7, 8 and tau pathologies.9, 10, 11, 12. The gene discussed is MAPT; the disease is Alzheimer disease.